Zydelig Interactions
There are 895 drugs known to interact with Zydelig (idelalisib), along with 7 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 232 are major, 645 are moderate, and 18 are minor.
- View all 895 medications that may interact with Zydelig
- View Zydelig alcohol/food interactions (1)
- View Zydelig disease interactions (7)
Most frequently checked interactions
View interaction reports for Zydelig (idelalisib) and the medicines listed below.
- Actemra (tocilizumab)
- Adcetris (brentuximab)
- Adempas (riociguat)
- Adriamycin RDF (doxorubicin)
- Alimta (pemetrexed)
- allopurinol
- Aptivus (tipranavir)
- aspirin
- atenolol
- Avastin (bevacizumab)
- Banzel (rufinamide)
- Baraclude (entecavir)
- Bexxar (iodine i 131 tositumomab)
- bleomycin
- Blincyto (blinatumomab)
- Crixivan (indinavir)
- Entyvio (vedolizumab)
- Farydak (panobinostat)
- Isentress (raltegravir)
- Juxtapid (lomitapide)
- Kalydeco (ivacaftor)
- Kynamro (mipomersen)
- omeprazole
- Pomalyst (pomalidomide)
- Prolia (denosumab)
- Revlimid (lenalidomide)
- Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil)
- Tecentriq (atezolizumab)
- Truvada (emtricitabine / tenofovir disoproxil)
- Tylenol (acetaminophen)
Zydelig alcohol/food interactions
There is 1 alcohol/food interaction with Zydelig (idelalisib).
Zydelig disease interactions
There are 7 disease interactions with Zydelig (idelalisib) which include:
- colitis
- dermatologic toxicities
- hepatic impairment
- infections
- intestinal perforation
- neutropenia
- lung toxicity
Report options
More about Zydelig (idelalisib)
- Zydelig consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: PI3K inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Kesimpta
Kesimpta (ofatumumab) is used to treat relapsing forms of multiple sclerosis. Includes Kesimpta ...
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Ibrutinib
Ibrutinib (Imbruvica) is a Bruton's tyrosine kinase inhibitor used for certain blood cancers and ...
Venetoclax
Venetoclax (brand name Venclexta) may be used to treat CLL, SLL, or AML in those aged 75 years or ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
